Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Sarcoma, Kaposi 1Neurofibromatosis 2 1Neurofibromatoses 1Neoplasms by Histologic Type 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1HIV Infections 1AIDS-related Kaposi sarcoma 1

Interventions

Carboplatin 4Sunitinib 3Rituximab 3Pemetrexed 3ponatinib 2pembrolizumab 2osimertinib 2Vincristine 2Prednisone 2Gemcitabine 2Etoposide 2Doxorubicin 2Cyclophosphamide 2ricolinostat 1pralsetinib 1pomalidomide 1nilotinib 1linifanib 1ibritumomab tiuxetan 1emvododstat 1atezolizumab 1Temozolomide 1Taxes 1Sorafenib 1Papanicolaou Test 1Paclitaxel 1Melphalan 1Irinotecan 1Interleukin-2 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms by Histologic Type × emvododstat × Clear all
NCT03761069 2022-02-02

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

PTC Therapeutics

Phase 1 Terminated
33 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡